Vivesto

0.13 SEK

-6.56 %

Less than 1K followers

VIVE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-6.56 %

-42.42 %

-43.04 %

-43.90 %

-54.83 %

-50.75 %

-72.13 %

-96.60 %

-99.28 %

Vivesto is a pharmaceutical company focused on developing innovative treatments for serious oncology diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Vivesto was founded in 1988 and is headquartered in Uppsala, Sweden.

Market cap

70.48M SEK

Turnover

127.93K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

22.12

2025

Extraordinary general meeting '25

27.2

2026

Annual report '25

7.5

2026

General meeting '26

All

Webcasts

Press releases

3rd party

ShowingAll content types

Press release11/24/2025, 7:00 AM

Vivesto holds a live-streamed business update today November 24

Press release11/21/2025, 6:40 AM

DNB Carnegie Access: Vivesto: Raising capital – Q3 review

Press release11/20/2025, 10:15 AM

DNB Carnegie Access: Vivesto - Q3 25 - Rapportintervju

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/20/2025, 7:35 AM

Notice of Extraordinary General Meeting in Vivesto AB

Regulatory press release11/20/2025, 7:30 AM

Vivesto resolves on a fully secured rights issue of approximately SEK 53.8 million, subject to approval by an Extraordinary General Meeting

Press release11/12/2025, 7:00 AM

Vivesto to hold live-streamed business update on November 24

Press release11/10/2025, 6:02 AM

DNB Carnegie Access: Vivesto: Positive interim readout from the Paccal Vet study

Regulatory press release11/7/2025, 2:15 PM

Vivesto reports positive interim results for Paccal Vet pilot study in dogs

Regulatory press release11/7/2025, 9:00 AM

Nomination Committee appointed for the Annual General Meeting 2026 in Vivesto

Press release11/5/2025, 11:56 AM

DNB Carnegie Access: Vivesto: Preclinical package strengthened

Press release11/4/2025, 7:00 AM

Vivesto receives positive new Cantrixil preclinical results in AML

Press release8/14/2025, 6:00 AM

First patient dosed in Vivesto’s Paccal Vet dose-finding study in cats

Press release8/13/2025, 11:25 AM

DNB Carnegie Access: Vivesto: Minor delays, but data readout approaching – Q2 review

Press release5/8/2025, 4:53 PM

Carnegie Access: Vivesto: Paccal Vet data expected this summer – Q1(25) review

Regulatory press release5/8/2025, 8:30 AM

Report from Annual General Meeting in Vivesto AB

Regulatory press release4/8/2025, 6:00 AM

Notice of Annual General Meeting in Vivesto AB

Press release4/1/2025, 6:00 AM

Vivesto reports positive Cantrixil results in an animal hematological cancer model

Press release3/31/2025, 3:11 PM

Carnegie Access: Vivesto: Secures the full rights to Cantrixil

Regulatory press release3/31/2025, 6:00 AM

Vivesto signs deal with Kazia Therapeutics to acquire full Cantrixil rights

Press release3/18/2025, 11:08 AM

Carnegie Access: Vivesto: Licensing deal for Apealea announced with Zhida

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.